The Claim
Once-weekly subcutaneous retatrutide administration is associated with a significant reduction in both systolic and diastolic blood pressure in adults with overweight, obesity, and/or type 2 diabetes, indicating a potential for cardiovascular risk reduction that extends beyond weight loss.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking a weekly shot of a drug called retatrutide might help lower blood pressure in people who are overweight, obese, or have type 2 diabetes — and this benefit might happen even if they don’t lose much weight.
See the scientific wording
Once-weekly subcutaneous retatrutide is associated with a significant reduction in systolic and diastolic blood pressure in adults with overweight, obesity, and/or type 2 diabetes, suggesting potential cardiovascular risk reduction beyond weight loss.
Score breakdown, mechanism chain, raw evidence, ideal studies needed
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.